ALX Oncology Holdings Inc. (ALXO)

USD 1.84

(2.79%)

Annual Income Statements

(In USD)
Breakdown 2023 2022 2021 2020 2019 2018
Revenue - - - 1.18 Million 4.79 Million 2.06 Million
Cost of Revenue 836 Thousand 1.46 Million 736 Thousand 1.07 Million 4.36 Million 1.88 Million
Gross Profit -836 Thousand -1.46 Million -736 Thousand 107 Thousand 436 Thousand 187 Thousand
Operating Expenses 170.27 Million 127.43 Million 83.55 Million 43.77 Million 19.61 Million 13.87 Million
Selling, General and Administrative Expenses 28.48 Million 29.03 Million 23.38 Million 14.8 Million 3.31 Million 2.6 Million
Research and Development Expenses 141.79 Million 98.4 Million 60.17 Million 28.96 Million 16.3 Million 11.27 Million
Other Expenses - -260 Thousand 84 Thousand -404 Thousand -5000.00 -2000.00
Cost and Expenses 170.27 Million 127.43 Million 83.55 Million 44.84 Million 23.97 Million 15.75 Million
Operating Income -170.27 Million -127.43 Million -83.55 Million -43.66 Million -19.18 Million -13.68 Million
Interest Expense 1.56 Million - 13 Thousand 811 Thousand 21 Thousand -
Income Tax Expense - 64 Thousand -21 Thousand 241 Thousand 34 Thousand 45 Thousand
Earnings before Tax -160.8 Million -123.41 Million -83.48 Million -45.49 Million -19.2 Million -13.68 Million
Net Income -160.8 Million -123.48 Million -83.46 Million -45.74 Million -19.24 Million -13.73 Million
Earnings Per Share Basic -3.74 -3.03 -2.07 -1.15 -0.53 -0.63
Earnings Per Share Diluted -3.74 -3.03 -2.07 -1.15 -0.53 -0.63
Weighted Average Shares Outstanding 42.98 Million 40.69 Million 40.3 Million 39.84 Million 36.48 Million 21.95 Million
Weighted Average Shares Outstanding (Diluted) 42.98 Million 40.69 Million 40.3 Million 39.84 Million 36.48 Million 21.95 Million
Gross Margin - - - 0.09 0.09 0.09
EBIT Margin - - - -37.28 -3.91 -6.41
Profit Margin - - - -38.70 -4.01 -6.64
EBITDA -158.4 Million -121.95 Million -83.47 Million -43.46 Million -18.75 Million -13.25 Million
Earnings Before Tax Margin - - - -36.94 -4.00 -6.62

Income Statement Charts